Truqap (Capivasertib)

Capivasertib is a medicine used to treat some advanced breast cancers and prostate cancers that have certain gene changes. It is taken as a pill by mouth, together with other cancer medicines. It works by blocking a protein called AKT that helps cancer cells grow.

Brand names:Truqap
Medication

What people taking Truqap (Capivasertib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Truqap (Capivasertib) for Breast Cancer?

NameHow it went

About Truqap (Capivasertib)

What It's For

Capivasertib, sold as Truqap, is a targeted cancer pill for two kinds of advanced cancer whose tumors carry specific genetic changes. It is not used on its own; it is added to a hormone-directed treatment. In breast cancer, it is taken with fulvestrant (Faslodex, a hormone therapy given by injection) by adults whose cancer is hormone receptor (HR)-positive and HER2-negative, meaning it grows in response to estrogen and is not driven by the HER2 protein. The cancer must be locally advanced or have spread (metastatic), and must have grown during earlier hormone treatment for advanced disease or come back within a year of finishing hormone therapy after surgery. In prostate cancer, it is taken with abiraterone (a hormone-blocking pill) and prednisone (a steroid) by adults whose cancer has spread and still responds to treatment that lowers male hormones (called hormone-sensitive or castration-sensitive). In both cases, a test on tumor tissue decides who is eligible. For breast cancer, the test looks for changes in the PIK3CA, AKT1 or PTEN genes. For prostate cancer, it looks for loss of the PTEN protein, called PTEN deficiency. The benefit in studies was seen mainly in tumors with these findings, which is why the medicine is reserved for them.

How It Works

Inside cells, a chain of signaling proteins called the PI3K/AKT pathway works like an accelerator for growth and survival. In some cancers, a change in the PIK3CA or AKT1 gene keeps this accelerator pressed down, or loss of PTEN, a protein that normally acts as a brake on the pathway, leaves it unchecked. AKT sits at a central point in the chain. Capivasertib blocks all three forms of AKT, cutting off growth signals these tumors rely on. In laboratory studies it slowed tumor growth on its own and together with hormone treatment, and it is approved only as part of those combinations. The aim is to keep the cancer from growing for longer, not to remove it.

Dosage & Administration

Truqap comes as tablets taken by mouth twice a day, about 12 hours apart, with or without food. The schedule is unusual: tablets are taken for 4 days in a row, followed by 3 days off, and the pattern repeats every week. The usual dose is 400 mg twice a day, taken as two tablets. The care team may lower it in steps if side effects call for it. Swallow the tablets whole with water. Do not chew, crush or split them, and do not take a tablet that is broken or cracked. A missed dose can still be taken within 4 hours of the usual time; after that, skip it and take the next dose as scheduled. If you vomit after a dose, do not take an extra one. The partner medicines continue on their own schedules: fulvestrant is an injection into the muscle given at the clinic, while abiraterone and prednisone are daily pills. Women who have not gone through menopause usually also receive medicine that switches off hormone production by the ovaries. People with prostate cancer continue testosterone-lowering treatment unless they have had both testicles removed.

Side Effects

Diarrhea is the most common side effect. It affected about three in four people taking Truqap for breast cancer and about half in the prostate cancer study, and it often begins within the first two weeks. At the first sign, start the antidiarrheal medicine the care team recommends, drink more fluids and let the team know, because diarrhea can become severe enough to cause dehydration. Skin reactions are also common, affecting roughly half of people: rash, itching, dry skin, or redness and soreness of the palms and soles. Many are treated with steroid creams or a pause in doses, but some become severe, so report a new or worsening rash, or red or peeling skin, to the care team right away. Nausea, tiredness, vomiting, mouth sores and lower appetite are other common effects. High blood sugar (hyperglycemia) is the side effect that needs the closest watching. Capivasertib can raise blood sugar, sometimes severely, including rare cases of diabetic ketoacidosis (a dangerous buildup of acids in the blood), and severe high blood sugar has been fatal. It was more frequent in the prostate cancer study, where blood sugar rose in about two thirds of people and about four in ten needed a diabetes medicine started or changed. Contact the care team right away for excessive thirst, urinating more often, blurred vision or a bigger appetite with weight loss. Call 911 or go to the emergency room for confusion or unusual drowsiness, trouble breathing, or nausea and vomiting with high blood sugar, which can mean ketoacidosis. Routine blood tests may also show lower blood counts, higher triglycerides (a type of blood fat) or changes in kidney tests, which the team tracks during treatment.

Interactions & Warnings

Capivasertib is processed by CYP3A, a drug-processing enzyme, so medicines that block or speed up that enzyme change how much of it stays in the body. Strong blockers, such as the antifungal itraconazole, raise its levels and side effects; the team usually avoids them or lowers the Truqap dose, and also lowers the dose alongside moderate blockers such as the antibiotic erythromycin or the heart and blood pressure medicine verapamil. Medicines that speed up the enzyme, such as the antibiotic rifampin, can make Truqap less effective and should be avoided. Grapefruit products may also interact with it and should be avoided. Check with the care team or pharmacist before starting any prescription, over-the-counter medicine, vitamin or herbal product. Because of the blood sugar risk, Truqap is paused during situations that make severe high blood sugar or ketoacidosis more likely, such as a suspected serious infection or another sudden illness. It helps to agree in advance with the team what to do if you become unwell. People with type 2 diabetes need closer glucose checks and may need stronger diabetes treatment. Its safety has not been established in type 1 diabetes or in type 2 diabetes that needs insulin or is poorly controlled, because those people were left out of the studies. Capivasertib can harm a developing baby. Women who could become pregnant should use effective contraception during treatment and for 1 month after the last dose, and men with a partner who could become pregnant should do so during treatment and for 4 months after. Breastfeeding is not recommended during treatment. Anyone who has had a severe allergic reaction to Truqap or its ingredients should not take it.

What to Expect

Before starting, the care team checks fasting blood sugar and HbA1c, a blood test that reflects average blood sugar over the past three months, and brings them under control if needed. Fasting glucose is then checked often during the first two months, usually on day 3 or 4 of a dosing week, and monthly after that, with HbA1c every three months. Some people check their own fasting glucose at home. Diarrhea and skin reactions tend to show up in the first few weeks, while blood sugar problems can appear early or many months into treatment. Truqap is continued for as long as the cancer stays under control and the side effects are manageable, with scans at regular intervals to check whether it is working. Pauses and dose reductions are common: in the breast cancer study about four in ten people had doses interrupted and about one in five had the dose lowered. These adjustments are a normal way of keeping treatment going, not a sign that it has failed. In the main breast cancer study, adding capivasertib to fulvestrant lengthened the typical time before the cancer grew from about 3 months to about 7 months, and tumors shrank in about a quarter of people, compared with under one in ten on fulvestrant alone. It did not significantly lengthen overall survival. In prostate cancer, it extended the typical time before scans showed the cancer growing from about 26 to 33 months; whether it helps people live longer was not yet known at that analysis. Responses vary, and the team weighs the benefit against side effects as treatment goes on.

Questions to Ask Your Doctor

  1. 1.What did the test on my tumor show, and how does that make Truqap a fit for me compared with other options?
  2. 2.What benefit can I realistically expect, and how will we tell from scans whether it is working?
  3. 3.How often will my blood sugar be checked, should I test at home, and what should I do if I get sick or my readings rise?
  4. 4.Which antidiarrheal medicine should I keep on hand, and when should I call about diarrhea or a rash?
  5. 5.Do any of my current medicines or supplements need to change while I take Truqap?

Last reviewed • Oct 2026

Educational content, not medical advice.